Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

• Status: Terminated
• Trial end date: 2020-04-30
• Target enrollment: 0
• Participant gender: All

Summary

In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is no clinical studies on the reduction of viral load in patients with COVID-19. This study investigate whether lopinavir/ritonavir or hydroxychloroquine reduces viral load from respiratory specimen in patients with mild COVID-19.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asan Medical Center
• Treatments: Hydroxychloroquine; Lopinavir; Ritonavir

Criteria

Inclusion Criteria:

• confirmed mild COVID-19 (NEWS scoring system 0-4)

Exclusion Criteria:

• unable to take oral medication

• pregnancy or breast feeding

• immunocompromised patients

• creatinine clearance (CCL) < 30 mL/min

• aspartate transaminase (AST) or alanine transaminase (ALT) > 5 times Upper limit of normal (ULN)